Spark Therapeutics Inc. (ONCE)

45.18
1.30 2.90
NASDAQ : Health Technology
Prev Close 43.89
Open 44.00
Day Low/High 43.52 / 45.93
52 Wk Low/High 34.53 / 96.59
Volume 356.50K
Avg Volume 588.10K
Exchange NASDAQ
Shares Outstanding 37.22M
Market Cap 1.62B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor

Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor

Biotech columnist Adam Feuerstein answers readers' questions about health care.

The Numbers Behind Biotech's Horrible, No Good, Awful August

The Numbers Behind Biotech's Horrible, No Good, Awful August

Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.

Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief

Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief

Speculative biotech stocks that were huge winners for healthcare investors earlier this year are now down significantly from their 52-week highs.

Spark Therapeutics Reports Second Quarter 2015 Results

Spark Therapeutics Reports Second Quarter 2015 Results

Confirming Guidance for Phase 3 Data Readout for SPK-RPE65 in 2015; Pipeline Advancing and Expanding

Jim Cramer: Spark Therapeutics (ONCE) Is Capable of Doing Amazing Things

Jim Cramer: Spark Therapeutics (ONCE) Is Capable of Doing Amazing Things

Spark Therapeutics (ONCE) stock is rising after Jim Cramer spoke with co-founder and CEO Jeff Marrazzo on CNBC's Mad Money show Wednesday night.

Jim Cramer's Top Takeaways: Live Nation, Spark Therapeutics, Ambarella

Jim Cramer's Top Takeaways: Live Nation, Spark Therapeutics, Ambarella

Cramer says Fitbit, Ambarella and GoPro may not be too expensive to own with their growth rates and market potential.

Jim Cramer's 'Mad Money' Recap: Road to China Is Lined With Bears and Bulls

Jim Cramer's 'Mad Money' Recap: Road to China Is Lined With Bears and Bulls

Cramer is not worried about Apple, and suggests viewers sit back and wait until the post-earnings panic subsides.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer sees a week bookended by Greece and the monthly jobs report, with many company earnings for good measure.

'Mad Money' Lightning Round: Buy, Buy, Buy Celgene; I'm a Believer

'Mad Money' Lightning Round: Buy, Buy, Buy Celgene; I'm a Believer

Cramer said Chevron's too cheap, he likes Sun Edison over Canadian Solar and wants you to buy Box.

Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen

Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen

Today the Federal Reserve told us what we already knew about the U.S. economy, Cramer says.

Bluebird Sickle Cell Gene Therapy Results Keep Getting Better

Bluebird Sickle Cell Gene Therapy Results Keep Getting Better

Six months after infusion with the Bluebird gene therapy known as LentiGlobin, almost half of the oxygen-carrying red blood cells in a single patient are normal and functioning.

Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease

Bluebird Bio First Look at Gene Therapy for Sickle Cell Disease

After four and a half months of follow-up, the sickle cell patient's blood contained 24% 'marked' beta globin, a measure of normally functioning hemoglobin, Bluebird announced Thursday.

Spark Therapeutics Drops After Rival Blindness Therapy Effectiveness Declines

Spark Therapeutics Drops After Rival Blindness Therapy Effectiveness Declines

Shares of Spark Therapeutics, a company investigating gene therapy whose most advanced product candidate, is being studied as a treatment of rare blinding conditions, is falling in early trading...

Gene Therapy Stocks on Watch Following Failure of Celladon's Heart Failure Trial

Gene Therapy Stocks on Watch Following Failure of Celladon's Heart Failure Trial

Will the failure of Celladon's Mydicar gene therapy bring other high-flying gene therapy stocks down to Earth?

IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up

IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up

Etsy and Virtu made a quite a splash with their Nasdaq debuts this week but is it enough to bring the U.S. IPO market out of its 2015 lull?

The Top 5 Best IPO Performers in the Last Year

The Top 5 Best IPO Performers in the Last Year

These are the top five best IPO performers in the last 12 months.

Biotech Stocks Still Feeling Healthy Despite Bubble Talk

Biotech Stocks Still Feeling Healthy Despite Bubble Talk

Shareholders feeling vertigo following the steep run-up in healthcare and biotech stocks need not reach for the medicine cabinet or the exit, says Marshall Gordon, Research Analyst at ClearBridge Investments.

Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy

Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy

In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.

'Mad Money' Lightning Round: I LIke H&R Block, RR Donnelley

'Mad Money' Lightning Round: I LIke H&R Block, RR Donnelley

Cramer wants you to avoid Pacific Ethanol, Sanchez Energy and Micron but buy, buy, buy Alcoa.

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

It's creating investment opportunities that just shouldn't exist, Cramer says.

IPO Roundup: Shake Shack Shares More Than Double Out of Gate

IPO Roundup: Shake Shack Shares More Than Double Out of Gate

Investors were eating up shares of Shake Shack as the stock more than doubled after the fast-casual burger chain's stock debuted on the New York Stock Exchange.

TheStreet Quant Rating: D (Sell)